How much of the EPS increase was driven by one-time items?

The sale of one priority review voucher contributed about $0.52 per share, or roughly $89 million pre-tax, to both GAAP and Non-GAAP EPS. Without it, GAAP diluted EPS would have declined 14% and Non-GAAP diluted EPS would have grown about 18%, rather than 31%.

Is LEQEMBI's launch meaningfully contributing to revenue yet?

LEQEMBI generated approximately $40 million of global in-market sales in Q2 2024, including about $30 million in the U.S., showing sequential acceleration. This remains small relative to Biogen's roughly $2.5 billion quarterly revenue base, and Biogen books only its 50% share of net LEQEMBI product revenue.

Why is full-year revenue guided lower even though EPS guidance was raised?

Management expects continued MS product revenue declines, which are partly offset by new product launches. Lower revenue is being outweighed by improved cost of sales as a percentage of revenue (product mix, no idle capacity charges) and lower operating expenses from the Fit for Growth and R&D prioritization programs, which together support mid-to-high teens operating income growth.

How did the HI-Bio acquisition and the PRV sale affect the balance sheet?

Biogen used $1.15 billion of cash to acquire Human Immunology Biosciences after quarter-end, which is not reflected in the June 30 figures. The PRV sale provided proceeds that management plans to reinvest in growth initiatives in 2024. Biogen also repaid the $1.0 billion 2023 term loan, and it made no share repurchases in the quarter.

What are the main risks to the outlook?

The guidance excludes potential acquisitions, large business development deals, pending litigation, and possible tax or healthcare reform impacts. The continued decline in MS revenue, the pace of new launch uptake (including LEQEMBI and SKYCLARYS), and foreign exchange assumptions as of July 26, 2024, are key variables. Management also noted that GAAP results may be affected by unpredictable items such as impairments and equity investment gains or losses.

BIIB 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Biogen reported second-quarter 2024 results on August 1, 2024, with total revenue of $2.46 billion^a, flat year-over-year at actual currency and up 1% at constant currency.

GAAP diluted EPS was $4.00^b (down 2%), while Non-GAAP diluted EPS was $5.28 (up 31%). The headline EPS improvement is flattered by an approximately $0.52 per share benefit from selling one of the company's two priority review vouchers (PRV), with an $89 million gain. Excluding the PRV sale, GAAP diluted EPS declined 14% and Non-GAAP diluted EPS rose 18%, so investors should look past the reported headline growth when judging underlying operating momentum.

Core pharmaceutical revenue (product revenue plus LEQEMBI) grew 5% at actual currency and 6% at constant currency. Growth was driven by rare disease (SKYCLARYS at $100 million^c and SPINRAZA-led franchise revenue up 22%) and new launches, including LEQEMBI with roughly $40 million of global in-market sales in the quarter. These gains offset a 5% decline in multiple sclerosis product revenue, which remains the core pressure point.

Operating efficiency improved, with non-GAAP R&D down 21% and no idle capacity charges in the quarter, supported by the Fit for Growth and R&D prioritization programs. Management raised full-year 2024 Non-GAAP EPS guidance to $15.75 to $16.25^d, from $15.00 to $16.00, implying roughly 9% growth at the midpoint versus 2023. Total revenue is now expected to decline by a low-single-digit percentage (improved from low-to-mid single digits), and operating income is expected to grow in the mid-to-high teens.

The company also completed the acquisition of Human Immunology Biosciences for $1.15 billion, repaid its $1.0 billion 2023 term loan, and ended the quarter with net debt of about $4.4 billion. No shares were repurchased in the quarter, leaving $2.1 billion under the existing authorization.

02—Key points

Key Highlights

Q2 2024 total revenue of $2,465 million, flat YoY at actual currency and up 1% at constant currency; product revenue rose 3% to $1,900 million.
GAAP diluted EPS of $4.00 (down 2% YoY) and Non-GAAP diluted EPS of $5.28 (up 31% YoY); both include a $0.52/share benefit from selling one priority review voucher.
Excluding the PRV sale, Non-GAAP diluted EPS rose 18% and GAAP diluted EPS fell 14% YoY.
Rare disease revenue rose 22% to $534 million, led by SKYCLARYS ($100 million) and SPINRAZA; MS product revenue declined 5% to $1,150 million.
FY2024 Non-GAAP EPS guidance raised to $15.75–$16.25 (about 9% growth at midpoint); total revenue now expected to decline by a low-single-digit percentage.
Q2 operating cash flow of $626 million and free cash flow of $592 million; net debt of about $4.4 billion at June 30, 2024, after the $1.15 billion HI-Bio acquisition closed after quarter-end.
Terminated the ATV:Aβ Alzheimer's program with Denali Therapeutics; the company also decided to retain its biosimilars business.

03—Questions

Frequently Asked Questions

How much of the EPS increase was driven by one-time items?
The sale of one priority review voucher contributed about $0.52 per share, or roughly $89 million pre-tax, to both GAAP and Non-GAAP EPS. Without it, GAAP diluted EPS would have declined 14% and Non-GAAP diluted EPS would have grown about 18%, rather than 31%.
Is LEQEMBI's launch meaningfully contributing to revenue yet?
LEQEMBI generated approximately $40 million of global in-market sales in Q2 2024, including about $30 million in the U.S., showing sequential acceleration. This remains small relative to Biogen's roughly $2.5 billion quarterly revenue base, and Biogen books only its 50% share of net LEQEMBI product revenue.
Why is full-year revenue guided lower even though EPS guidance was raised?
Management expects continued MS product revenue declines, which are partly offset by new product launches. Lower revenue is being outweighed by improved cost of sales as a percentage of revenue (product mix, no idle capacity charges) and lower operating expenses from the Fit for Growth and R&D prioritization programs, which together support mid-to-high teens operating income growth.
How did the HI-Bio acquisition and the PRV sale affect the balance sheet?
Biogen used $1.15 billion of cash to acquire Human Immunology Biosciences after quarter-end, which is not reflected in the June 30 figures. The PRV sale provided proceeds that management plans to reinvest in growth initiatives in 2024. Biogen also repaid the $1.0 billion 2023 term loan, and it made no share repurchases in the quarter.
What are the main risks to the outlook?
The guidance excludes potential acquisitions, large business development deals, pending litigation, and possible tax or healthcare reform impacts. The continued decline in MS revenue, the pace of new launch uptake (including LEQEMBI and SKYCLARYS), and foreign exchange assumptions as of July 26, 2024, are key variables. Management also noted that GAAP results may be affected by unpredictable items such as impairments and equity investment gains or losses.

04—Continue

← View all 8-K filings